Dataset from A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support

Teduglutide is approved for treatment of adults with short bowel syndrome (SBS). The purpose
of this study is to evaluate the safety and efficacy of teduglutide in children up to the age
of 17 with SBS who are dependent on parenteral support. Subjects may choose whether to
receive the study drug or to participate in a standard-of-care arm. All participants who
complete the study may be eligible to receive the study drug in a long-term extension study.